Status:
COMPLETED
Pharmacogenomics of Antiplatelet Response
Lead Sponsor:
Johns Hopkins University
Conditions:
Atherosclerosis
Eligibility:
All Genders
45-75 years
Phase:
PHASE4
Brief Summary
This clinical trial will examine with effect of 2-week aspirin therapy on platelet gene expression in persons at high-risk of developing heart attacks due to family history of early-onset coronary art...
Detailed Description
In this clinical trials we will select individuals from GeneSTAR cohort based o their platelet function. Equal number of individuals will be selected from each race and gender and from low or high pla...
Eligibility Criteria
Inclusion
- 45-75 years
- GeneSTAR participant
- No personal History of Coronary Artery Disease
- Women who are post-menopausal
- Women who are using a reliable method of contraception, such as history of tubal ligation, IUD or taking OCP
Exclusion
- Taking aspirin prescribed by physician
- weight \< 60 kg
- History of recent or current bleeding
- allergy to aspirin or history of adverse events to aspirin
- serious comorbid conditions (such as AIDS, active cancer)
- high blood pressure (\>160/95)
- History of gastrointestinal ulcer/bleeding
- Mental incompetence to make decision to participate.
Key Trial Info
Start Date :
June 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2015
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT02234427
Start Date
June 1 2014
End Date
May 1 2015
Last Update
January 9 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins School of Medicine
Baltimore, Maryland, United States, 21287